FDA OKs Esketamine Nasal Spray Monotherapy for Depression ...Middle East

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants. Medscape Medical News

Hence then, the article about fda oks esketamine nasal spray monotherapy for depression was published today ( Friday 24/01/2025 - 08:27 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA OKs Esketamine Nasal Spray Monotherapy for Depression )

Also on site :

• Musk mulling mega-mergers – Bloomberg
• Iconic ‘90s Heavy Metal Band Announces Change Ahead of Final Australian Tour
• Kurdish-led SDF agrees integration with Syrian government forces